SUNNYVALE, Calif., Jan. 11, 2011 /PRNewswire/ — Accuray Incorporated (Nasdaq:
ARAY), a global leader in the field of radiosurgery, announced
today the first published five-year outcomes on low risk prostate
cancer patients treated with the CyberKnife®
Robotic Radiosurgery System. The multi-center study, published
in the January 10, 2011 issue of Radiation Oncology, found
that 93 percent of patients had no recurrence of their cancer at a
median follow-up of five years, a rate that compares favorably to
results obtained with other treatment modalities, including surgery
and conventional radiation therapy.
The study, “Stereotactic Body
Radiotherapy for Low-Risk Prostate Cancer: Five-Year Outcomes,”
combined data from 41 patients treated at Stanford University in
Stanford, Calif. and Naples Community Hospital in Naples, Fla. with
a median follow-up of five years. The paper represents the longest
published study to date on the use of CyberKnife radiosurgery, also
referred to as stereotactic body radiotherapy (SBRT), as a
treatment approach for clinically localized, low-risk prostate
cancer. In addition to demonstrating high five-year disease-free
survival rates, the study also found generally low levels of
urinary and rectal toxicity following the five-day course of
treatment, concluding that CyberKnife radiosurgery can
achieve high rates of disease control while sparing critical
structures, thereby minimizing undesirable side effects typically
associated with prostate cancer treatments and preserving patients’
quality of life.
“As a non-invasive treatment option completed in just five
visits, stereotactic radiotherapy with the CyberKnife System offers
pati
‘/>”/>
SOURCE